- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- FDA advisory panel to consider OTC status of NSAIDs
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Diplomat becomes distributor of recently approved cancer drug
SHAWNEE, Kan. — Bayer's Advantage Multi for Dogs (imidacloprid + moxidectin) received Food and Drug Administration approval as the first-ever treatment for circulating microfilaria in heartworm-positive dogs. The approval was referenced in American Heartworm Society guidelines surrounding heartworm prevention and treatment.
"Bayer is passionate about caring for animals and develops products and services that support veterinarians' ability to keep our pets healthy," Cristiano von Simson, DVM, MBA, director of Veterinary Technical Services at Bayer HealthCare Animal Health division, North America, said. "These updated guidelines, and the FDA's recognition of the importance of treating microfilaria, will strengthen veterinarians' capability to reduce the incidence and severity of heartworm disease in dogs."
There are conservatively 1 million cases of heartworm disease diagnosed in dogs every year, according to AHS. Heartworm disease most commonly results in abnormal functioning of the lungs, heart, liver and kidneys.